

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

PROPOSED ELECTION OF THE SECOND SESSION OF THE BOARD; AND PROPOSED ELECTION OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

PROPOSED ELECTION OF THE SECOND SESSION OF THE BOARD

Pursuant to the relevant laws and regulations and the articles of association of the Company (the “**Articles of Association**”), the term of office of the board (the “**Board**”) of directors (the “**Directors**”) of the Company shall be three years and upon expiry of such term, the Directors shall be eligible to offer themselves for re-election and be re-appointed subject to the approval of shareholders of the Company (the “**Shareholders**”) at a general meeting. The current session of the Board will be expired on 29 December 2023. As such, the Board has resolved to elect the second session of the Board at an extraordinary general meeting (the “**EGM**”). The term of the second session of the Board will be three years commencing from the date of approval at the EGM.

The Board is pleased to announce that:

- Dr. He Chao has been nominated for re-election as an executive Director for the second session of the Board;
- each of Mr. Sun Hongbin and Mr. Chen Chen has been nominated for re-election, and Mr. Chen Xinxing has been nominated for election, as a non-executive Director for the second session of the Board; and
- each of Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong has been nominated for re-election as an independent non-executive Director for the second session of the Board.

Upon the conclusion of the EGM, Mr. Sun Xin will retire from office as a non-executive Director and cease to be a member of the audit committee (the “**Audit Committee**”) of the Company. Mr. Sun Xin has confirmed that he has no disagreement with the Board, and there are no other matters that need to be brought to the attention of the Shareholders or the Stock Exchange.

The Board has assessed and reviewed the written confirmation of independence of each of Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong based on the independence criteria as set out in Rule 3.13 of the Listing Rules and considered them to be independent. The Board has also assessed and evaluated the experience of Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong based on the nomination policy of the Company which was disclosed in the annual report of the Company and believes that the valuable knowledge and experience of them in the respective area of medicine, law and finance would generate significant contribution to the Company and the Shareholders as a whole and diversity of the Board.

The biographical details of each of the candidates (the “**Proposed Director Candidates**”) to the second session of the Board are as follows:

Executive Director

Dr. He Chao (何超), aged 38, was appointed as the Director on 18 October 2017 and redesignated as the executive Director on 10 June 2021. He is the president of the Company and is mainly responsible for overseeing the research and development and day-to-day management and strategic development of the Group. He is also a member of the nomination committee (the “**Nomination Committee**”) and the strategy and development committee (the “**Strategy and Development Committee**”) of the Company.

Dr. He Chao has over 15 years of experience in the research and development of surgical robots. He joined the Group as the general manager of the Company in May 2015 and has been serving as the president since December 2020, primarily responsible for the business operations of the Company. Dr. He Chao also holds various directorships and management positions in the Group companies, including but not limited to the executive director of Suzhou MicroPort OrthoBot Co., Ltd. (蘇州微創暢行機器人有限公司) (“**OrthoBot Suzhou**”) since July 2019, the representative of the Beijing branch of the Company since November 2020 and the representative of the Shanghai branch of OrthoBot Suzhou since July 2022.

Prior to joining the Group, from June 2013 to April 2014, Dr. He Chao served as the system engineer of Chinese Academy of Space Technology (中國空間技術研究院), a spacecraft designer and manufacturer, where he was mainly responsible for system engineering and project management. From April 2014 to May 2015, Dr. He Chao served as the senior director of Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司) (“**Shanghai MicroPort**”), a medical device manufacturer and an indirect wholly-owned subsidiary of the MicroPort, where he was primarily responsible for research and development (“**R&D**”) and project management of surgical robots.

Dr. He Chao serves as the Chinese representative in the technical committee for the preparation of international technical standards for surgical robots of International Electrotechnical Commission, a global organization which builds international standards and conformity assessment systems to ensure the safety, efficiency, reliability and interoperability of electrical, electronic and information technologies. He is also a member of the first expert panel of China's medical robot technical standardization unit and the director of Shanghai Engineering Research Center of Minimally Invasive Surgical Robots (上海微創手術機器人工程技術研究中心) sponsored by the Science and Technology Commission of Shanghai Municipality (上海市科學技術委員會).

Dr. He Chao graduated from Hefei University of Technology in China (the “**PRC**”) with a bachelor's degree in mechanical and electronics in July 2007 and graduated from Tianjin University in the PRC with a doctor's degree in mechanical engineering in January 2014. During his Ph.D. study at Tianjin University, Dr. He Chao spent the 2011–12 academic year at Johns Hopkins University in the United States as a visiting scholar.

As at the date of this announcement, Dr. He Chao was interested in 617,023,912 H shares of the Company, representing approximately 64.37% of the total issued shares in the Company.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into a service contract with Dr. He Chao. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the service contract and during his tenure as a senior management of the Company, Dr. He Chao will not receive any remuneration from the Group for his office as an executive Director and solely receives remuneration from the Group in his capacity as a senior management. The remuneration is determined by the Board on a combined basis of various factors, such as the duties of his position, actual performance and with reference to the external industry remuneration standards. For the year ended 31 December 2022, the remuneration of Dr. He Chao was RMB2.496 million (before tax) which was determined by the Board on the recommendation of the remuneration and appraisal committee (the “**Remuneration and Appraisal Committee**”) of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Non-executive Directors

Mr. Sun Hongbin (孫洪斌), aged 48, was appointed as the Director on 3 April 2020 and redesignated as the non-executive Director on 10 June 2021. He is serving as the chairman of the Board and is primarily responsible for overseeing the management and operations of the Group. He is also the chairperson of the Strategy and Development Committee and a member of the Remuneration and Appraisal Committee.

Mr. Sun Hongbin has over 20 years of experience in the medical device industry. Mr. Sun Hongbin joined MicroPort Scientific Corporation (微創醫療科學有限公司) (the “**MicroPort**”) and its subsidiaries, associate and joint venture (the “**MicroPort Group**”) in September 2010 and has served in various positions in the MicroPort Group. Mr. Sun Hongbin is currently serving as the chief

financial officer, a rotating chairperson of the Greater China Executive Committee and a member of the Intercontinental Cardiac Rhythm Management Committee of MicroPort. He has also been serving as the chief financial officer of Shanghai MicroPort, a subsidiary of MicroPort, since September 2010.

Mr. Sun Hongbin has served as an independent non-executive director of a number of listed companies, including New Century Healthcare Holding Co. Limited (新世紀醫療控股有限公司), a company principally engaged in provision of medical services in pediatrics and obstetrics and gynecology whose shares are listed on the Stock Exchange (stock code: 1518), since December 2016, CStone Pharmaceuticals (基石藥業), a biopharmaceutical company whose shares are listed on the Stock Exchange (stock code: 2616), since February 2019, and Mobvista Inc. (匯量科技有限公司), a technology platform providing mobile advertising and mobile analytics services whose shares are listed on the Stock Exchange (stock code: 1860), since July 2020, and Abbisko Cayman Limited (和譽開曼有限責任公司), a clinical-stage biopharmaceutical company whose shares are listed on the Stock Exchange (stock code: 2256), since September 2021.

Prior to joining the MicroPort Group, from 1998 to 2003, Mr. Sun Hongbin served as an assistant manager of the Shanghai Branch of KPMG Accounting firm (畢馬威會計師事務所上海辦事處), where he was primarily responsible for audit work. From 2004 to 2010, Mr. Sun Hongbin was the financial director and later the director and general manager of Otsuka (China) Investment Co., Ltd. (大冢(中國)投資有限公司), a company principally engaged in healthcare investment management services, where he was primarily responsible for its overall management.

Mr. Sun Hongbin graduated from Shanghai Jiao Tong University in the PRC with a bachelor's degree in economics in 1998. Mr. Sun Hongbin is a member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) and is also a Chartered Financial Analyst.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Mr. Sun Hongbin. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Mr. Sun Hongbin will not receive any remuneration from the Group for his office as a non-executive Director.

Mr. Chen Xinxing (陳新星), aged 38, was nominated by the Board as a candidate for the non-executive Director on 1 December 2023.

Mr. Chen Xinxing joined Boston Consulting Group as a senior associate from September 2007 to August 2010. He then joined Morgan Stanley as an associate in the China healthcare team of the investment banking division from August 2012 to April 2014. Mr. Chen Xinxing served as a principal of the China healthcare team of Actis Capital, LLP from April 2014 to May 2018. From September 2018 to March 2020, Mr. Chen Xinxing served as an executive director of Huaxing Healthcare Fund (華興醫療產業基金). Since July 2020, Mr. Chen Xinxing joined Hillhouse Investment, in which he currently acts as a managing director. Mr. Chen Xinxing has been serving as a non-executive director of Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司) (whose H-shares were listed and traded on the Stock Exchange on 10 October 2022, stock code: 9877) since May 2021.

Mr. Chen Xinxing obtained his bachelor's degree in finance from Peking University in the PRC in July 2007 and received a master's degree in business administration from Columbia University in May 2012. Mr. Chen Xinxing is qualified as a Chartered Financial Analyst.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Mr. Chen Xinxing. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Mr. Chen Xinxing will not receive any remuneration from the Group for his office as a non-executive Director.

Mr. Chen Chen (陳琛), aged 40, was appointed as the Director on 17 September 2020 and was re-designated as the non-executive Director on 10 June 2021. He is primarily responsible for overseeing the management and operations of the Group.

Mr. Chen Chen has 12 years of experience in the business consulting and investment management industry. From July 2015 to December 2018, Mr. Chen Chen worked at Shanghai Panxin Equity Investment Management Limited (上海盤信股權投資管理有限公司) where he held various positions, including investment manager, senior investment manager and vice president. From January 2019 to September 2020, he served as a principal at Tianjin Panmao Enterprise Management Limited Liability Partnership (天津盤茂企業管理合夥企業(有限合夥)). Since September 2020, he has successively served as a principal and executive general manager at Beijing Panmao Investment Management Co., Ltd. (北京盤茂投資管理有限公司) (“CPE”). Prior to joining the investment management industry, Mr. Chen Chen was a consultant at the Shanghai branch of Bain & Company from October 2009 to August 2013.

Mr. Chen Chen is currently also serving as a director of several other companies, including, a non-executive director of Shanghai Hanyu Medical Technology Co., Ltd. (上海捍宇醫療科技股份有限公司), a director of Spectrum Dynamics Medical Group Limited and was a non-executive director of Acotec Scientific Holdings Limited (先瑞達醫療科技控股有限公司) from December 2020 to February 2023.

Mr. Chen Chen graduated from Shanghai Jiao Tong University in the PRC with a bachelor's degree in electronic engineering in July 2005. He received his first master's degree in industry economics from Shanghai Jiao Tong University in the PRC in March 2009, and his second master's degree in business administration from University of Chicago in the United States in June 2015.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Mr. Chen Chen. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Mr. Chen Chen will not receive any remuneration from the Group for his office as a non-executive Director.

Independent non-executive Directors

Dr. Li Minghua (李明華), aged 71, was appointed as an independent Director on 30 December 2020, and was re-designated as the independent non-executive Director on 10 June 2021. He is also the chairperson of the Remuneration and Appraisal Committee and a member of the Audit Committee of the Company and the Strategy and Development Committee.

Dr. Li Minghua joined the radiology department of Shanghai Sixth People's Hospital (上海市第六人民醫院放射科) in December 1992 as a vice-chief physician, and became a chief physician and professor in January 1997. From January 2000 to May 2018, he successively served as the chairman and doctoral supervisor of the department of diagnostic and neurointerventional radiology of Shanghai Sixth People's Hospital (上海市第六人民醫院放射科及神經介入診治中心) and a director of the institute of medical imaging of Shanghai Jiao Tong University (上海交通大學醫學影像研究所). He served as the chief physician and professor of the Shanghai Sixth People's Hospital (上海市第六人民醫院) from May 2018 to February 2019 and has been serving as an emeritus professor since March 2019.

Dr. Li Minghua graduated from the Shanghai First Medical College (currently known as Fudan University) in the PRC in September 1973. He received his master's degree in neuro-imaging/CT from Graduate School of the Shanghai Medical University (currently known as Fudan University) in the PRC in October 1988, and his doctor's degree in neuro-imaging/MRI in Lund University in Sweden in January 1993. From 1994 to 1995, Dr. Li Minghua pursued a post-doctoral program in the field of interventional neuroradiology as a visiting scholar in University San Raffaele Milan in Italy.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Dr. Li Minghua. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Dr. Li Minghua is entitled to a director's fee of RMB120,000 per annum (before tax), which was determined by the Board on the recommendation of the Remuneration and Appraisal Committee with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Mr. Yao Haisong (姚海嵩), aged 49, was appointed as the independent Director on 30 December 2020, and was re-designated as the independent non-executive Director on 10 June 2021. He is also the chairperson of the Nomination Committee and a member of the Remuneration and Appraisal Committee.

From March 2002 to June 2004, Mr. Yao Haisong served as an assistant researcher, legal manager and secretary to the chairman of the board of directors of Shanghai Biochip Co., Ltd. (上海生物芯片有限公司), a biotech company, where he was primarily responsible for research and legal matters.

Mr. Yao Haisong has over 15 years of working experience in law firms. Since July 2004, Mr. Yao has been serving as a practicing lawyer, and he later served as a partner of Shanghai Huzhong Law Firm (上海市滬中律師事務所), where he was primarily responsible for providing legal advice. From July 2011 to February 2015, he served as a practising lawyer and patent attorney of the Beijing Yingke

(Shanghai) Law Firm (北京盈科(上海)律師事務所). Since February 2015, Mr. Yao Haisong has been serving as a practising lawyer and partner of Shanghai Tianhua Law Firm (上海市天華律師事務所), where he was primarily responsible for providing business related legal advice.

Mr. Yao Haisong graduated from Shanghai Second Medical University in the PRC with a bachelor's degree in clinical medicine in July 2000. He received a second bachelor's degree in jurisprudence from Shanghai University in the PRC in July 2002, and his master's degree in international business law from National University of Singapore in Singapore in June 2008. Mr. Yao Haisong is currently serving as a part-time researcher of Intelligent Medicine Institute, Fudan University (復旦大學智能醫學研究院), a member of China Research Hospital Association Clinical Data and Bio-bank a standing committee member (中國研究型醫院學會臨床數據與樣本資源庫專業委員會), a committee member of National Technical Committee on Bio-specimen of Standardization Administration of China (全國生物樣本標準化技術委員會) (SAC/TC559).

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Mr. Yao Haisong. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Mr. Yao Haisong is entitled to a director's fee of RMB120,000 per annum (before tax), which was determined by the Board on the recommendation of the Remuneration and Appraisal Committee with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Mr. Mui Wing Hong (梅永康), aged 52, was appointed as the independent non-executive Director on 21 June 2022. He is also the chairperson of the Audit Committee and a member of the Nomination Committee.

Mr. Mui Wing Hong has more than 25 years' experience in managing various finance and accounting activities that included financial reporting, budgeting, internal control, fund raising and taxation of listed company.

Mr. Mui Wing Hong is a fellow of The Hong Kong Institute of Certified Public Accountants, a member of the American Institute of Certified Public Accountants, and is a fellow of The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly known as the Institute of Chartered Secretaries and Administrators). Mr. Mui Wing Hong graduated from The Chinese University of Hong Kong with a bachelor's degree in business administration majoring in accounting in December 1994 and further completed a chief financial officer (CFO) program at China Europe International Business School (中歐國際工商學院) in November 2008 and Northwestern University (Kellogg School of Management) and The Hong Kong University of Science and Technology Executive MBA in December 2020.

From 1994 to 1997, Mr. Mui Wing Hong served as an audit senior at BDO Limited. From to 1997 to 2003, Mr. Mui Wing Hong served as an audit manager at the KPMG Hong Kong branch. From 2004 to 2007, Mr. Mui Wing Hong served as the group finance manager of the Global Beauty Group. From October 2007 to December 2020, Mr. Mui Wing Hong served as the general manager (group finance)

of Shui On Land Limited (瑞安房地產有限公司) (stock code: 00272), a company listed on the Stock Exchange. From January 2021 to February 2022, Mr. Mui Wing Hong served as the deputy general manager (finance) of K. Wah International Holdings Limited (嘉華國際集團有限公司) (stock code: 00173), a company listed on the Stock Exchange. From April 2022 to July 2022, Mr. Mui Wing Hong served as the director of Max Advisory Limited. Since August 2022, he has been serving as the financial controller of South Asia Real Estate Group Co., Ltd. (南益地產集團有限公司).

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into an appointment letter with Mr. Mui Wing Hong. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Board expires. Pursuant to the appointment letter, Mr. Mui Wing Hong is entitled to a director's fee of RMB120,000 per annum (before tax), which was determined by the Board on the recommendation of the Remuneration and Appraisal Committee with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Save as disclosed above, each of the Proposed Director Candidates has confirmed that as at the date of this announcement, (i) he does not hold any other positions with the Company and/or any of its subsidiaries; (ii) he does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) he does not have any relationships with any Directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) he does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, each of the Proposed Director Candidates has confirmed that, there are no other matters relating to the proposed appointment that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment that need to be brought to the attention of the Shareholders.

PROPOSED ELECTION OF SECOND SESSION OF THE SUPERVISORY COMMITTEE

Pursuant to the relevant laws and regulations and the Articles of Association, the term of office of the supervisors of the Company (the “**Supervisors**”) shall be three years and upon expiry of such term, the shareholder representative Supervisors shall be eligible to offer themselves for re-election and re-appointment subject to the approval of Shareholders at a general meeting, while the employee representative Supervisor shall be eligible to offer themselves for re-election and re-appointment subject to the election at the employee representatives' meeting. The current session of the supervisory committee (the “**Supervisory Committee**”) of the Company will expire on 29 December 2023. As such, the shareholder representative Supervisors of the second session of the Supervisory Committee will be elected at the EGM. Each of Dr. Zhang Jie and Ms. Zhang Lihong has been nominated for re-election as a Supervisor for the second session of the Supervisory Committee. The election of the employee representative Supervisor of the second session of the Supervisory Committee will be

considered and approved at the employee representative meeting of the Company to be convened in due course and shall not be subject to the approval of the Shareholders. The term of the second session of the Supervisory Committee will be three years commencing from the date of approval at the EGM.

The biographical details of each of the candidates (the “**Proposed Supervisor Candidates**”) (except for the employee representative Supervisor) to the second session of the Supervisory Committee are as follows:

Dr. Zhang Jie (張劼), aged 44, was appointed as the Supervisor on December 2020 and is serving as the chairman of the Supervisory Committee on 30 December 2020. He is primarily responsible for supervising and providing independent advice to the Board.

Dr. Zhang Jie joined the MicroPort Group in January 2007 and has successively served as an equipment engineer, research and development director, senior director, vice president of Shanghai MicroPort, where he has been primarily responsible for the research and development of medical devices. Dr. Zhang Jie is currently serving as an acting chief technology officer, a member and a chief technology officer of the Greater China Executive Committee of MicroPort, he also holds various directorships in a number of other members of the MicroPort Group.

Dr. Zhang Jie graduated from Zhejiang University of Technology in the PRC with a bachelor’s degree in communication principles in 2002. He received his master’s degree in measuring and testing technologies and instruments from University of Shanghai for Science and Technology in the PRC in March 2007, and received his doctor’s degree in biomedical engineering from University of Shanghai for Science and Technology in the PRC in August 2021.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into a service contract with Dr. Zhang Jie. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Supervisory Committee expires. Dr. Zhang Jie will not receive any remuneration from the Group as a Supervisor.

Ms. Zhang Lihong (張麗紅), aged 46, was appointed as the Supervisor on 30 December 2020. She is primarily responsible for supervising and providing independent advice to the Board.

Ms. Zhang Lihong joined the MicroPort Group in June 2013 and has since successively served in various positions in MicroPort Group, including as intellectual property manager, intellectual property director, senior intellectual property director, vice president of intellectual property and legal affair and senior vice president of intellectual property, where she has been primarily responsible for the management of intellectual property affairs. Ms. Zhang Lihong also holds directorships and management positions in a number of other members of the MicroPort Group.

Prior to joining the MicroPort Group, from 2003 to 2006, she worked at Shanghai Microelectronics Equipment Co., Ltd. (上海微電子裝備有限公司), a company principally engaged in development of semiconductor equipment, where she was primarily responsible for intellectual property and standardization management. From 2006 to 2009, Ms. Zhang Lihong served as manager of Central Research Institute of Shanghai Radio and Television (Group) Co., Ltd. (上海廣電(集團)有限公司中央

研究院), a company principally engaged in electronic device industry in the field of broadcast and television, where she was primarily responsible for intellectual property management. Ms. Zhang Lihong also served as a senior intellectual property manager of Shanghai Shipeng Laboratory Technology Development Co., Ltd. (上海世鵬實驗室科技發展有限公司), a company principally engaged in providing R&D and sales for medical devices, from 2009 to 2011, and manager of the intellectual department and legal department of Shanghai United Imaging Healthcare Co., Ltd. (上海聯影醫療科技股份有限公司) a company principally engaged in R&D and production of medical devices, from 2011 to 2013, where she was primarily responsible for intellectual property management and legal affairs.

Ms. Zhang Lihong has also been serving as a specially-invited expert of national technology transfer personnel training base (國家技術轉移人才培養基地), a member of Shanghai Scientific and Technological Achievements Transformation and Standardization Technical Committee (上海市科技成果轉化標委會), a director of Shanghai Intellectual Property Research Association (上海知識產權研究會), the first batch of overseas intellectual property dispute response guidance experts, an expert of the Think-tank of Shanghai Technology Exchange (上海市技術交易所專家智庫), a vice president of Pudong New Area Intellectual Property Association (浦東新區知識產權協會) and vice president of Intellectual Property Association of China (Shanghai) Pilot Free Trade Zone (中國(上海)自由貿易試驗區知識產權協會).

Ms. Zhang Lihong graduated from the Xian Technological University in the PRC with a bachelor's degree in detection technology and equipment in July 2000. She received her master's degree in measurement and control technology and equipment from Xian University of Technology in the PRC in 2004.

Subject to the approval of the Shareholders by way of an ordinary resolution at the EGM, the Company will enter into a service contract with Ms. Zhang Lihong. The initial length of service will commence from the date of the EGM and end when the term of the second session of the Supervisory Committee expires. Ms. Zhang Lihong will not receive any remuneration from the Group as a Supervisor.

Save as disclosed above, each of the Proposed Supervisor Candidates has confirmed that as at the date of this announcement, (i) he or she does not hold any other positions with the Company and/or any of its subsidiaries; (ii) he or she does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) he or she does not have any relationships with any Directors, Supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) he or she does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, each of the Proposed Supervisor Candidates has confirmed that, there are no other matters relating to the proposed appointment that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment that need to be brought to the attention of the Shareholders.

GENERAL

The Company will convene and hold the EGM for the Shareholders to consider and, if thought fit, approve, among others, the proposed appointment of Directors of the second session of the Board and the proposed appointment of shareholder representative Supervisors of the second session of the Supervisory Committee.

A circular containing, among others, (i) details of the proposed appointment of Directors of the second session of the Board and the proposed appointment of Supervisors of the second session of the Supervisory Committee; and (ii) a notice of the EGM, will be despatched to the Shareholders in due course.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 1 December 2023

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.